



# Market Announcement

26 February 2024

---

## Heramed Limited (ASX: HMD) – Suspension from Quotation

### Description

The securities of Heramed Limited ('HMD') will be suspended from quotation immediately under Listing Rule 17.2, at the request of HMD, in relation to an announcement to the market regarding a material new contract.

### Issued by

Listings Compliance

**ASX ANNOUNCEMENT****26 February 2024**

Lisa Banh  
Adviser, Listings Compliance  
ASX Operations  
20 Bridge Street  
SYDNEY NSW 2000

Via Email: [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

Dear Ms Banh

**REQUEST FOR VOLUNTARY SUSPENSION**

Medical technology company, **HeraMED Limited (ASX:HMD)** (“HeraMED” or the “Company”) requests immediate suspension of the Company’s securities in accordance with ASX Listing Rule 17.2.

The suspension is requested in relation to an announcement to the market regarding a material new contract (**Purpose**).

In accordance with ASX Listing Rule 17.2, the Company provides the following information in relation to the request:

1. The suspension is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the Purpose above before the commencement of normal trading on Wednesday, 28 February 2024.
2. The Company requests the suspension to remain in place until the earlier of commencement of normal trading on Wednesday, 28 February 2024 or when the announcement regarding the Purpose is released to the market.
3. The Company is not aware of any reason why the voluntary suspension should not be granted or any other information necessary to inform the market about the suspension.

Your faithfully

**Jonathan Hart**  
Company Secretary

**-ENDS-**